CAS 571190-30-2

General Information

Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

About the API

Trade name(s) Ibrance
Technology Synthetic
Molecular Formula C24H29N7O2
Molecular Weight 447.533 g/mol
Therapeutic category Oncology
Available formulations Oral Solid
Regulations US DMF Flag US DMF